Analysis of Risk Factors Affecting the Pediatric Renal Allograft Survival in Cyclosporine Era.
- Author:
Pyung Kil KIM
1
;
Won Kyu CHOI
;
Ji Hong KIM
;
Myoung Soo KIM
;
Jin Wook CHOI
;
Yu Seung KIM
;
Soon II KIM
;
Ki Il PARK
Author Information
1. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Pediatric;
Renal transplantation;
Graft survival;
Risk factors
- MeSH:
Allografts*;
Compliance;
Cyclosporine*;
Dialysis;
Glomerulonephritis, IGA;
Graft Survival;
Immunosuppressive Agents;
Kidney Failure, Chronic;
Kidney Transplantation;
Prednisolone;
Risk Factors*;
Transplants
- From:Korean Journal of Nephrology
1998;17(1):116-123
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A total of 82 pediatric renal transplants treated with cyclosporine and low dose prednisolone as the main immunosuppressive agents were used as the subjects of this study to find the risk factors whitch might influence the pediatric renal allograft survival in a single center from Feb. 1984 to Mar. 1996. The mean age of the recipients was 14.7 years ranging from ages 3.9 to 19.9. There were 19 cases of graft loss, and 3 recipient death. The major causes of the graft loss were acute and/or chronic rejection, poor compliance and patient's death. The 1-, 3- and 5-year graft survival were 94.9%, 86.2% and 70.7% respectively. The original renal deseases of ESRD were FSGS (14 cases), chronic pyelonephropathy and VUR (11 cases) and IgA nephropathy (8 cases) in order frequency. The significant risk factors for the outcome were the ABO incompatibility (ABO identical 89.6% vs compatible 26.9%, P=0.001) and development of more than 1 episode of acute rejection within 1 year (P=0.002) and after 1 year (P=0.004). Other factors such as recipient's age, donor-recipient relationship and type and duration of dialysis modalities before trasplantation (P>0.05). In conclusion, for the successful outcome of pediatric renal transplantation, strict ABO matching and development and application of more effective immunosuppressive agents such as mycophenolate or FK- 506 to combat the acute and/or chronic rejection is required in near future.
